NASDAQ:XCUR 9 December 2025

Biggest Stock Gainers Today (December 9, 2025): AFJK, NCPL, XCUR, ALEX and DBI Lead the After‑Bell Rally

Aimei Health Technology shares surged 968% to $85.47 Tuesday after the SPAC extended its merger deadline to January 6, 2026, fueling speculation of a pending deal. The S&P 500 closed down 0.02%, while microcap stocks dominated gains, with Oriental Culture Holding up 321% and Netcapital up 122%. Trading in AFJK exceeded 6 million shares, far above its average.

9 December 2025

NASDAQ:AFJK·NASDAQ:BENF·NASDAQ:CYPH·NASDAQ:JXG·NASDAQ:LGHL·NASDAQ:NCPL·NASDAQ:OCG·NASDAQ:XCUR·NYSE:ALEX·NYSE:DBI·Stock Market

Exicure (XCUR) Stock Soars on Burixafor Phase 2 Data: What December 2025 Investors Need to Know

Exicure shares surged over 100% in pre-market trading December 9 after reporting positive topline Phase 2 results for burixafor in multiple myeloma at the ASH meeting. The trial met its primary endpoint in 17 of 19 patients, with no serious drug-related adverse events. XCUR closed at $5.33 on December 8, up 8.78%, and traded as high as $10.84 pre-market, pushing market cap to around $30–40 million.

9 December 2025

NASDAQ:XCUR·Pharmaceutical News·Stock Market

RTX Shares See 52% Gain in Year - Is It Overvalued at $200?
March 20, 2026, 1:45 AM EDT. RTX's share price rose 51.8% over the past year but dropped 1.4% last month, trading around $200.73. A Discounted Cash Flow (DCF) analysis values RTX at $183.11, suggesting the stock is about 9.6% overvalued based on projected free cash flows. Despite promising aerospace and defense sector positioning, valuation signals are mixed, with a 3 out of 6 score indicating both undervaluation and fair pricing factors. Investors should watch RTX closely for market shifts and updates to fundamentals that could affect its value.